Borrás-Blasco J, Valcuende-Rosique A, Alcala R, Cornejo-Uixeda S. Long-term persistence comparison between guselkumab and secukinumab for the treatment of psoriasis. World J Dermatol 2026; 12(1): 121180 [DOI: 10.5314/wjd.121180]
Corresponding Author of This Article
Joaquin Borrás-Blasco, PhD, PharmD, Department of Pharmacy, Hospital de Sagunto, Av. Ramón Y Cajal s/n, Puerto de Sagunto 46520, Spain. jborrasb@gmail.com
Research Domain of This Article
Dermatology
Article-Type of This Article
research-article
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Share the Article
Borrás-Blasco J, Valcuende-Rosique A, Alcala R, Cornejo-Uixeda S. Long-term persistence comparison between guselkumab and secukinumab for the treatment of psoriasis. World J Dermatol 2026; 12(1): 121180 [DOI: 10.5314/wjd.121180]
Joaquin Borrás-Blasco, Silvia Cornejo-Uixeda, Department of Pharmacy, Hospital de Sagunto, Puerto de Sagunto 46520, Spain
Alejandro Valcuende-Rosique, Department of Pharmacy, Hospital Universitario de la Ribera, Alzira 46600, Spain
Rebeca Alcala, Department of Dermatology, Hospital de Sagunto, Sagunto 46250, Spain
Author contributions: Borrás-Blasco J conceived and designed the study; Valcuende-Rosique A, Alcala R, Borrás-Blasco J, and Cornejo-Uixeda S designed the statistical analysis and extracted data; Valcuende-Rosique A, Alcala R, Borrás-Blasco J, and Cornejo-Uixeda S performed the analysis, and drafted and revised the manuscript; and all authors read and approved the final manuscript.
AI contribution statement: No AI tool was involved in the generation of research data, interpretation of results, or formulation of conclusions.
Institutional review board statement: The study was approved by the hospital’s Clinical Research Ethics Committee with the code IIS-F-PG-27-04 and was conducted in accordance with the principles of the Declaration of Helsinki.
Informed consent statement: The requirement for informed consent was waived by the Institutional Review Board/Ethics Committee because of the retrospective nature of the study. All data were collected and analyzed anonymously, and no identifiable personal information was included.
Conflict-of-interest statement: All authors declare that they have no conflict of interest to disclose.
STROBE statement: The authors have read the STROBE Statement-checklist of items, and the manuscript was prepared and revised according to the STROBE Statement-checklist of items.
Data sharing statement: Not applicable.
Corresponding author: Joaquin Borrás-Blasco, PhD, PharmD, Department of Pharmacy, Hospital de Sagunto, Av. Ramón Y Cajal s/n, Puerto de Sagunto 46520, Spain. jborrasb@gmail.com
Received: March 24, 2026 Revised: May 30, 2026 Accepted: June 29, 2026 Published online: September 16, 2026 Processing time: 181 Days and 15.7 Hours
Abstract
BACKGROUND
Psoriasis is a chronic immune-mediated inflammatory skin disease. Biologic therapies have revolutionized psoriasis management because of their high efficacy and favorable safety profiles. Several biologic agents are available for the treatment of moderate to severe psoriasis. Treatment persistence, defined as the duration from therapy initiation to discontinuation, is crucial for assessing therapeutic success in real-world clinical practice. This study aimed to compare the long-term treatment persistence of secukinumab and guselkumab in patients with moderate to severe psoriasis over a four-year follow-up period.
AIM
To compare the long-term treatment persistence of secukinumab and guselkumab in patients with moderate to severe psoriasis over a four-year follow-up period.
METHODS
We conducted a retrospective observational study involving adult patients with moderate to severe psoriasis who initiated treatment with secukinumab or guselkumab between January 1, 2015 and June 30, 2024. Demographic, clinical, and treatment-related data were collected from two hospitals. The Kaplan-Meier method was applied to estimate treatment persistence over a four-year follow-up period.
RESULTS
A total of 149 patients were analyzed: 87 initiated secukinumab and 62 initiated guselkumab. The persistence rate for guselkumab was higher at 12 months (98.2% vs 82.8%), 24 months (93.0% vs 75.3%), 36 months (87.7% vs 67.9%), and 48 months (87.7% vs 57.3%) compared with secukinumab, with a significant difference in overall persistence between groups (log-rank P = 0.003). No significant differences in persistence were observed based on whether patients were biologic-naïve or biologic-experienced for either treatment. Discontinuation rates were 20.7% for secukinumab and 4.8% for guselkumab, with lack of effectiveness being the primary reason for discontinuation.
CONCLUSION
Guselkumab was associated with higher long-term persistence than secukinumab in this real-world cohort.
Core Tip: This study contributes to the current body of knowledge by providing real-world data on the long-term persistence of secukinumab and guselkumab in patients with moderate to severe psoriasis. The findings indicate that guselkumab is associated with significantly higher long-term persistence compared with secukinumab, highlighting the relevance of treatment selection in clinical decision-making. The insights gained from this study can guide healthcare providers in optimizing therapy with guselkumab and secukinumab, ultimately leading to improved patient outcomes and more effective treatment strategies.
